Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-25T19:48:41.228Z Has data issue: false hasContentIssue false
  • English
  • Français

Antidepressant Effects of Atypical Antipsychotics

Published online by Cambridge University Press:  07 November 2014

Roy H. Perlis
Get access Rights & Permissions [Opens in a new window]

Extract

Studies have shown that there is some efficacy for a number of agents, most notably lithium, in treating bipolar depression. However, the studies also highlight the unfortunate reality that many patients fail to respond adequately to first-line therapies and that there is a need to identify additional options for patients and clinicians. The atypical antipsychotics clozapine, olanzapine, quetiapine, risperidone, ziprasidone, and aripiprazole, have been the focus of increased interest in the treatment of bipolar depression.

The use of antipsychotics in the treatment of depressive episodes is not a particularly novel idea. In 1982, Robertson and Trimble reviewed 34 studies examining the use of typical antipsychotics to augment an antidepressant and noticed modest but generally consistent benefits. More widespread use of these agents in the management of depression has been limited, however, because of concerns about the long-term risk of tardive dyskinesia and the induction of extrapyramidal symptoms that often mimic depressive symptoms.

Clozapine, the first of the atypicals, was applied initially in the treatment of schizophrenia and schizoaffective disorder, where antidepressant effects were noted during open treatment. Subsequent case series described some benefit in dysphoric manias in bipolar disorder as well.

Much of the inditect evidence for antidepressant effects of the atypicals came from studies in major depressive disorder (MDD). For example, a series of eight patients with MDD who failed treatment with a selective serotonin reuptake inhibitor (SSRI) achieved marked and rapid response when risperidone was added to the SSRI. All patients remitted within 1 week; Hamilton Rating Scale for Depression score in these patients declined from a mean of 20.5 to a mean of 2.4 (Slide 11). A subsequent series of 30 patients yielded similar results.

Type
Research Article
Information
CNS Spectrums , Volume 8 , supplement S12: Treatment of Bipolar Depression , December 2003 , pp. 6 - 8
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Robertson, MM, MR, Trimble. Major tranquilizers used as antidepressants. J Affect Disord. 1982;4:173–193.CrossRefGoogle ScholarPubMed
2.Suppes, T, McElroy, SL, Gilbert, J, Dessain, EC, JO, Cole. Clozapine in the treatment of dysphoric mania. Biol Psychiatry. 1992;32:270–280.CrossRefGoogle ScholarPubMed
3.Ostroff, RB, JC, Nelson. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60:256–259.CrossRefGoogle ScholarPubMed
4.Hirose, S, Ashby, CR Jr. An open pilot study combining risperidone and a selective setotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry. 2002;63:733–736.Google Scholar
5.Papakostas, GI, Peterson, T, Nierenberg, AA, et al.Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. In press.Google Scholar
6.Shelton, RC, Tollefson, GD, Tohen, M, et al.A novel augmentation strategy fot treating resistant major depression. Am J Psychiatry. 2001;158:131–134.CrossRefGoogle Scholar
7.Dube, S, Anderson, SW, Paul, S, et al. Meta-analysis of olanzapine-fluoxetine use to treatment-resistent depression. Poster presented at: Annual Meeting of the European College of Neuropsychopharmacology; 10 5-9, 2002; Barcelona, Spain.Google Scholar
8.RC, Shelton. The combination of olanzapine and fluoxetine in mood disorders. Expert Opin Pharmacother. 2003;4:1175–1183.Google Scholar
9.Baker, RW, Tohen, M, Fawcett, J, et al.Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol. 2003;23:132–137.CrossRefGoogle ScholarPubMed
10.Tohen, M, Chengappa, KN, Suppes, T, et al.Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62–69.CrossRefGoogle ScholarPubMed
11.Sajatovic, M, Mullen, JA, DE, Sweitzer. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry. 2002;12:1156–1163.CrossRefGoogle Scholar
12.Vieta, E, Goikolea, JM, Corbella, B, et al.Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry. 2001;62:818–825.CrossRefGoogle ScholarPubMed
13.Suppes, T, Webb, A, Paul, B, Carmody, T, Kraemer, H, AJ, Rush. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual fot patients with treatment-resistant illness and a history of mania. Am J Psychiatry. 1999;156:1164–1169.CrossRefGoogle Scholar
14.Post, RM, Leverich, GS, Nolen, WA, et al.A reevaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Bipolar Treatment Network. Bipolar Disord. 2003. In press.Google Scholar
15.Stahl, S, Shelton, R. Poster presented at: Annual Meeting of the American Psychiatric Association; 05 2001; New Orleans, La.Google Scholar
16.Tohen, M, et al. Postet ptesented at: Annual Meeting of the American Psychiatric Association; 05 2002; Philadelphia, PA.Google Scholar
17.Johnson, RE, BH, McFarland. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry. 1996;153:993–1000.Google Scholar
18.Tohen, M, Hennen, J, Zarate, CM Jr., et al.Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157:220–228.CrossRefGoogle ScholarPubMed
19.Sussman, N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol. 2003;23:S21–26.CrossRefGoogle ScholarPubMed
20.Allison, DB, Mentore, JL, Heo, M, et al.Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156:1686–1696.CrossRefGoogle ScholarPubMed
21.Reynolds, GP, Zhang, ZJ, XB, Zhang. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359:2086–2087.CrossRefGoogle ScholarPubMed
22.Prien, RF, Caffey, EM Jr., CJ, Klett. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and NIMH Collaborative Study Group. Arch Gen Psychiatry. 1972;26:146–153.CrossRefGoogle Scholar
23.Zhang, W, Perry, KW, Wong, DT, et al.Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000;23:250–262.CrossRefGoogle ScholarPubMed
24.Lattanti, L, Dell'Osso, L, Cassano, P, et al.Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002;4:307–314.CrossRefGoogle Scholar
25.Angst, F, Stassen, HH, Clayton, PJ, Angst, J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68:167–181.CrossRefGoogle ScholarPubMed
26.Meltzer, HY, Alphs, L, Green, AI, et al.Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial. Arch Gen Psychiatry. 2003;60:82–91.CrossRefGoogle ScholarPubMed
27.Hirschfeld, RA, CL, Bowden, Gitlin, MJ, et al.Practice guideline for the treatment of patients with bipolat disorder (revision). Am J Psychiatry. 2002;159:1–50.Google Scholar